STOCK TITAN

[Form 4] Virios Therapeutics, Inc. Common Stock Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

First US Bancshares, Inc. (FUSB) – Form 4 filing: Director Jack W. Meigs reported the routine quarterly crediting of 32.64 phantom stock units on 06/30/2025 under the company’s Non-Employee Directors’ Deferred Compensation Plan. The units convert to common stock on a 1-for-1 basis and were booked at an implied price of $12.90 per unit, lifting the director’s total phantom holdings to 6,080.04 units. Ownership remains direct; settlement will occur at the end of the elected deferral period. No open-market purchase or sale of common shares occurred, and there is no change in the director’s voting power until conversion. The filing reflects standard compensation accrual, with negligible dollar value (≈ $420) and no apparent signal of material change in insider sentiment or corporate outlook.

First US Bancshares, Inc. (FUSB) – Deposito Form 4: Il direttore Jack W. Meigs ha segnalato l'accredito trimestrale ordinario di 32,64 unità di azioni fantasma il 30/06/2025 nell'ambito del Piano di Compensazione Differita per Amministratori Non Dipendenti della società. Le unità si convertono in azioni ordinarie con un rapporto di 1 a 1 e sono state registrate a un prezzo implicito di $12,90 per unità, portando il totale delle azioni fantasma detenute dal direttore a 6.080,04 unità. La proprietà rimane diretta; il regolamento avverrà al termine del periodo di differimento scelto. Non si sono verificate operazioni di acquisto o vendita di azioni ordinarie sul mercato aperto, e non vi è alcuna variazione del potere di voto del direttore fino alla conversione. Il deposito riflette un accredito standard di compensi, con un valore in dollari trascurabile (≈ $420) e nessun segnale evidente di cambiamento sostanziale nel sentimento interno o nelle prospettive aziendali.

First US Bancshares, Inc. (FUSB) – Presentación del Formulario 4: El director Jack W. Meigs reportó el crédito trimestral rutinario de 32.64 unidades de acciones fantasma el 30/06/2025 bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa. Las unidades se convierten en acciones ordinarias en una proporción de 1 a 1 y se registraron a un precio implícito de $12.90 por unidad, elevando la tenencia total del director a 6,080.04 unidades. La propiedad sigue siendo directa; la liquidación ocurrirá al final del período de diferimiento elegido. No hubo compra ni venta en el mercado abierto de acciones comunes, y no hay cambio en el poder de voto del director hasta la conversión. La presentación refleja una acumulación estándar de compensación, con un valor monetario insignificante (≈ $420) y sin señales aparentes de un cambio material en el sentimiento interno o la perspectiva corporativa.

First US Bancshares, Inc. (FUSB) – Form 4 제출: 이사 Jack W. Meigs는 2025년 6월 30일 회사의 비임원 이사 연기 보상 계획에 따라 32.64 팬텀 스톡 단위의 정기 분기 적립을 보고했습니다. 해당 단위는 1대 1 비율로 보통주로 전환되며, 단위당 $12.90의 암시 가격으로 기록되어 이사의 총 팬텀 보유량은 6,080.04 단위로 증가했습니다. 소유권은 직접적으로 유지되며, 정산은 선택된 연기 기간 종료 시 이루어집니다. 보통주에 대한 공개 시장 매매는 없었으며, 전환 전까지 이사의 의결권 변화는 없습니다. 이번 제출은 표준 보상 적립을 반영하며, 금전적 가치는 미미(약 $420)하고 내부자 심리나 기업 전망에 중요한 변화 신호는 보이지 않습니다.

First US Bancshares, Inc. (FUSB) – Dépôt du formulaire 4 : Le directeur Jack W. Meigs a déclaré le crédit trimestriel habituel de 32,64 unités d’actions fantômes le 30/06/2025 dans le cadre du Plan de rémunération différée pour administrateurs non salariés de la société. Ces unités se convertissent en actions ordinaires au taux de 1 pour 1 et ont été comptabilisées à un prix implicite de 12,90 $ par unité, portant la détention totale du directeur à 6 080,04 unités. La propriété reste directe ; le règlement aura lieu à la fin de la période de différé choisie. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a eu lieu, et il n’y a pas de changement dans le pouvoir de vote du directeur jusqu’à la conversion. Le dépôt reflète une accumulation standard de rémunération, avec une valeur monétaire négligeable (≈ 420 $) et aucun signal apparent de changement significatif dans le sentiment des initiés ou les perspectives de l’entreprise.

First US Bancshares, Inc. (FUSB) – Form 4 Einreichung: Direktor Jack W. Meigs meldete die routinemäßige vierteljährliche Gutschrift von 32,64 Phantomaktieneinheiten am 30.06.2025 im Rahmen des Deferred Compensation Plans für nicht-angestellte Direktoren des Unternehmens. Die Einheiten werden im Verhältnis 1:1 in Stammaktien umgewandelt und wurden zu einem impliziten Preis von $12,90 pro Einheit verbucht, wodurch der Gesamtbestand des Direktors auf 6.080,04 Einheiten an Phantomaktien anstieg. Das Eigentum bleibt direkt; die Abwicklung erfolgt am Ende des gewählten Aufschubzeitraums. Es gab keinen Kauf oder Verkauf von Stammaktien am offenen Markt, und bis zur Umwandlung ändert sich die Stimmrechtsmacht des Direktors nicht. Die Einreichung spiegelt eine standardmäßige Vergütungsansammlung wider, mit einem vernachlässigbaren Geldwert (≈ $420) und ohne erkennbare Hinweise auf wesentliche Änderungen der Insiderstimmung oder der Unternehmensprognose.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine phantom unit accrual; immaterial size; neutral signal.

The transaction is an automatic, plan-based issuance of 32.64 phantom stock units worth roughly $0.4 k. Such deferred-compensation credits are common for outside directors and do not involve cash outlay or market purchase. Post-transaction holdings of 6,080 units represent less than 0.1 % of FUSB’s shares outstanding, offering no indication of strategic intent. Market impact is therefore de minimis.

First US Bancshares, Inc. (FUSB) – Deposito Form 4: Il direttore Jack W. Meigs ha segnalato l'accredito trimestrale ordinario di 32,64 unità di azioni fantasma il 30/06/2025 nell'ambito del Piano di Compensazione Differita per Amministratori Non Dipendenti della società. Le unità si convertono in azioni ordinarie con un rapporto di 1 a 1 e sono state registrate a un prezzo implicito di $12,90 per unità, portando il totale delle azioni fantasma detenute dal direttore a 6.080,04 unità. La proprietà rimane diretta; il regolamento avverrà al termine del periodo di differimento scelto. Non si sono verificate operazioni di acquisto o vendita di azioni ordinarie sul mercato aperto, e non vi è alcuna variazione del potere di voto del direttore fino alla conversione. Il deposito riflette un accredito standard di compensi, con un valore in dollari trascurabile (≈ $420) e nessun segnale evidente di cambiamento sostanziale nel sentimento interno o nelle prospettive aziendali.

First US Bancshares, Inc. (FUSB) – Presentación del Formulario 4: El director Jack W. Meigs reportó el crédito trimestral rutinario de 32.64 unidades de acciones fantasma el 30/06/2025 bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa. Las unidades se convierten en acciones ordinarias en una proporción de 1 a 1 y se registraron a un precio implícito de $12.90 por unidad, elevando la tenencia total del director a 6,080.04 unidades. La propiedad sigue siendo directa; la liquidación ocurrirá al final del período de diferimiento elegido. No hubo compra ni venta en el mercado abierto de acciones comunes, y no hay cambio en el poder de voto del director hasta la conversión. La presentación refleja una acumulación estándar de compensación, con un valor monetario insignificante (≈ $420) y sin señales aparentes de un cambio material en el sentimiento interno o la perspectiva corporativa.

First US Bancshares, Inc. (FUSB) – Form 4 제출: 이사 Jack W. Meigs는 2025년 6월 30일 회사의 비임원 이사 연기 보상 계획에 따라 32.64 팬텀 스톡 단위의 정기 분기 적립을 보고했습니다. 해당 단위는 1대 1 비율로 보통주로 전환되며, 단위당 $12.90의 암시 가격으로 기록되어 이사의 총 팬텀 보유량은 6,080.04 단위로 증가했습니다. 소유권은 직접적으로 유지되며, 정산은 선택된 연기 기간 종료 시 이루어집니다. 보통주에 대한 공개 시장 매매는 없었으며, 전환 전까지 이사의 의결권 변화는 없습니다. 이번 제출은 표준 보상 적립을 반영하며, 금전적 가치는 미미(약 $420)하고 내부자 심리나 기업 전망에 중요한 변화 신호는 보이지 않습니다.

First US Bancshares, Inc. (FUSB) – Dépôt du formulaire 4 : Le directeur Jack W. Meigs a déclaré le crédit trimestriel habituel de 32,64 unités d’actions fantômes le 30/06/2025 dans le cadre du Plan de rémunération différée pour administrateurs non salariés de la société. Ces unités se convertissent en actions ordinaires au taux de 1 pour 1 et ont été comptabilisées à un prix implicite de 12,90 $ par unité, portant la détention totale du directeur à 6 080,04 unités. La propriété reste directe ; le règlement aura lieu à la fin de la période de différé choisie. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a eu lieu, et il n’y a pas de changement dans le pouvoir de vote du directeur jusqu’à la conversion. Le dépôt reflète une accumulation standard de rémunération, avec une valeur monétaire négligeable (≈ 420 $) et aucun signal apparent de changement significatif dans le sentiment des initiés ou les perspectives de l’entreprise.

First US Bancshares, Inc. (FUSB) – Form 4 Einreichung: Direktor Jack W. Meigs meldete die routinemäßige vierteljährliche Gutschrift von 32,64 Phantomaktieneinheiten am 30.06.2025 im Rahmen des Deferred Compensation Plans für nicht-angestellte Direktoren des Unternehmens. Die Einheiten werden im Verhältnis 1:1 in Stammaktien umgewandelt und wurden zu einem impliziten Preis von $12,90 pro Einheit verbucht, wodurch der Gesamtbestand des Direktors auf 6.080,04 Einheiten an Phantomaktien anstieg. Das Eigentum bleibt direkt; die Abwicklung erfolgt am Ende des gewählten Aufschubzeitraums. Es gab keinen Kauf oder Verkauf von Stammaktien am offenen Markt, und bis zur Umwandlung ändert sich die Stimmrechtsmacht des Direktors nicht. Die Einreichung spiegelt eine standardmäßige Vergütungsansammlung wider, mit einem vernachlässigbaren Geldwert (≈ $420) und ohne erkennbare Hinweise auf wesentliche Änderungen der Insiderstimmung oder der Unternehmensprognose.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Whitley Richard James

(Last) (First) (Middle)
C/O DOGWOOD THERAPEUTICS, INC.
44 MILTON AVENUE

(Street)
ALPHARETTA GA 30009

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $4.71 06/27/2025 A 2,362 06/27/2026 06/27/2035 Common Stock 2,362 $0 2,362 D
Explanation of Responses:
/s/ Greg Duncan, Attorney-in-Fact 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many FUSB phantom stock units did Director Jack W. Meigs acquire on 06/30/2025?

He received 32.64 phantom stock units under the deferred compensation plan.

What is the total phantom stock balance Jack W. Meigs now holds in FUSB?

After the transaction, his balance is 6,080.04 phantom units.

At what price were the new FUSB phantom units credited?

The units were booked at an implied price of $12.90 per unit.

Do the phantom stock units convert into FUSB common shares?

Yes, they convert on a 1-for-1 basis into common stock at the end of the deferral period.

Was this a market purchase of FUSB shares?

No. It was a plan-based accrual; no open-market trade occurred.
Virios Therapeutics, Inc.

NASDAQ:VIRI

VIRI Rankings

VIRI Latest News

VIRI Latest SEC Filings

VIRI Stock Data

4.30M
27.76M
1.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
ALPHARETTA